Is Ankylosing Spondylitis an Autoimmune Disease
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 14, 2021 Category: General Medicine Source Type: news

Flagship-founded immunology startup bags $189M from Softbank, others
Repertoire Immune Medicines, the immunology startup formed last year by the merging of two Flagship Pioneering-founded companies, has secured $189 million as it looks to "decode" cancer, autoimmune disorders and infectious diseases, in that order. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 13, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
             Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progre...
Source: Roche Media News - April 8, 2021 Category: Pharmaceuticals Source Type: news

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
             Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progre...
Source: Roche Investor Update - April 8, 2021 Category: Pharmaceuticals Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

Screening for skin disease on your laptop
(University of Houston) A University of Houston biomedical engineer is reporting a new deep neural network architecture - to be used on a standard laptop - that provides early diagnosis of systemic sclerosis (SSc), a rare autoimmune disease marked by hardened or fibrous skin and internal organs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 6, 2021 Category: International Medicine & Public Health Source Type: news

Arthritis: Four stages of the progressive disease rheumatoid arthritis
ARTHRITIS can be a sign of an autoimmune condition, where the body mistakenly attacks its own joints. This is known as rheumatoid arthritis, which is a progressive disease. What are the warning signs? (Source: Daily Express - Health)
Source: Daily Express - Health - April 4, 2021 Category: Consumer Health News Source Type: news

Fred Miller retires from NIEHS Clinical Research Branch
During the past 40 years, he and his team have made some of the most groundbreaking discoveries in the study of autoimmune disease. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - April 2, 2021 Category: Environmental Health Source Type: news

Masonic Medical Research Institute awarded Department of Defense Lupus Impact Award
(Masonic Medical Research Institute) Lupus is a common and devastating autoimmune disease that has no cure and current treatments only work to improve symptoms, which often have secondary, even devastating, side effects. Therefore, there is significant need and urgency to identify more specific and targeted therapies for this disease. Dr. Maria Kontaridis, Executive Director at MMRI aims to try to do just this, with grant support from a newly garnered Department of Defense (DOD) Lupus Impact Award, totaling $750,000. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 2, 2021 Category: International Medicine & Public Health Source Type: news

Relationship between psoriasis treatments and cardiovascular risk explained
(Cactus Communications) Patients with psoriasis, an autoimmune skin disorder, often have cardiovascular disorders as well. Hence, it is important for patients and clinicians to understand how treatments for psoriasis may influence cardiovascular disease risks. A review article recently published in Chinese Medical Journal offers a useful summary of how the existing treatment options for psoriasis influence a patient's likelihood of experiencing cardiovascular events such as a heart attack. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2021 Category: International Medicine & Public Health Source Type: news

Rheumatoid arthritis symptoms: The three most commonly reported early warning signs
RHEUMATOID arthritis is an autoimmune disease, which means the body's immune system targets affected joints. Research suggests there are three common initial symptoms to watch out for. (Source: Daily Express - Health)
Source: Daily Express - Health - March 27, 2021 Category: Consumer Health News Source Type: news

Janssen Receives Positive CHMP Opinion for PONVORY ™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features
BEERSE, BELGIUM, MARCH 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for PONVORY™ (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.[3]“Relapsing forms of multiple sclerosis (MS) have varied and often unpredictable symptoms, posing a unique human, societal and economic burden,” said Catherine T...
Source: Johnson and Johnson - March 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine
(InSilico Medicine) AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 25, 2021 Category: Biology Source Type: news

COVID-19 vaccines may not produce sufficient antibody response in transplant recipients
(Johns Hopkins Medicine) When clinical trials were conducted to determine the immunogenicity -- the ability to elicit an immune response -- for the first two vaccines marshaled against SARS-CoV-2the virus that causes COVID-19, one group was not among those included: people who have received solid organ transplants and others (such as those with autoimmune disorders) who are immunocompromised. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 24, 2021 Category: Infectious Diseases Source Type: news

Biomarkers to Guide GC Replacement in Addison's Disease Biomarkers to Guide GC Replacement in Addison's Disease
A new study has identified promising new biomarkers to help guide glucocorticoid replacement dosages in autoimmune Addison's disease.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cancer immunotherapy may also treat certain autoimmune diseases
(Michigan Medicine - University of Michigan) The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 19, 2021 Category: Biology Source Type: news

Some Long Covid-19 Patients Feel Better After Vaccine Doses
It is too soon to tell whether the shots have a broad beneficial effect on patients with continuing issues, but scientists are intrigued and beginning to study the phenomenon. (Source: NYT Health)
Source: NYT Health - March 17, 2021 Category: Consumer Health News Authors: Pam Belluck Tags: your-feed-science Vaccination and Immunization Chronic Condition (Health) Coronavirus (2019-nCoV) Immune System Research Autoimmune Diseases Moderna Inc Pfizer Inc your-feed-healthcare Source Type: news

Immune receptor protein could hold key to treatment of autoimmune diseases
(Tokyo University of Science) TARM1 is a receptor protein whose role in the functioning of the immune system is unknown. In a new study, scientists from Japan have explored the potential role of TARM1 in the pathogenesis of rheumatoid arthritis by analyzing mouse models. They found that TARM1 activated dendritic cells, and development of collagen-induced arthritis (CIA) was notably suppressed in TARM1-deficient mice and by treatment with TARM1-inhibitory soluble TARM1 proteins. This makes the protein a potential therapeutic target. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news

Mayo Clinic Q & amp;A podcast: Rapid pace of COVID-19 vaccinations
Millions of people in the U.S. are being vaccinated for COVID-19. However, discussion is ongoing as to whether people who are immunocompromised, such as patients undergoing cancer treatment, or people who have autoimmune diseases, should be vaccinated for COVID-19. "Both of those categories (of people) should be vaccinated," says Dr. Gregory Poland, an infectious diseases expert [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 17, 2021 Category: Databases & Libraries Source Type: news

New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Lipid presentation by the protein C receptor links coagulation with autoimmunity
Antiphospholipid antibodies (aPLs) cause severe autoimmune disease characterized by vascular pathologies and pregnancy complications. Here, we identify endosomal lysobisphosphatidic acid (LBPA) presented by the CD1d-like endothelial protein C receptor (EPCR) as a pathogenic cell surface antigen recognized by aPLs for induction of thrombosis and endosomal inflammatory signaling. The engagement of aPLs with EPCR-LBPA expressed on innate immune cells sustains interferon- and toll-like receptor 7–dependent B1a cell expansion and autoantibody production. Specific pharmacological interruption of EPCR-LBPA signaling attenua...
Source: ScienceNOW - March 11, 2021 Category: Science Authors: Müller-Calleja, N., Hollerbach, A., Royce, J., Ritter, S., Pedrosa, D., Madhusudhan, T., Teifel, S., Meineck, M., Häuser, F., Canisius, A., Nguyen, T. S., Braun, J., Bruns, K., Etzold, A., Zechner, U., Strand, S., Radsak, M., Strand, D., G Tags: Immunology, Medicine, Diseases, Online Only r-articles Source Type: news

New compound targets enzyme linked to autoimmune disorders, severe COVID-19
(Nanyang Technological University) NTU Singapore scientists have created a compound that could help to reduce an overactive immune response by targeting an enzyme that helps to regulate the body's immune response. High levels of this enzyme has been linked to autoimmune disorders and, more recently, severe COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 10, 2021 Category: Infectious Diseases Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news

New method facilitates development of antibody-based drugs
(Lund University) In recent years, therapeutic antibodies have transformed the treatment of cancer and autoimmune diseases. Now, researchers at Lund University in Sweden have developed a new, efficient method based on the genetic scissors CRISPR-Cas9, that facilitates antibody development. The discovery is published inNature Communications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 5, 2021 Category: International Medicine & Public Health Source Type: news

Rheumatoid arthritis symptoms: Nodules under your skin are a visual clue of arthritis
RHEUMATOID arthritis is an autoimmune disease that causes a number of joint problems. Lumps under the skin of bony areas can signal you have rheumatoid arthritis. (Source: Daily Express - Health)
Source: Daily Express - Health - March 2, 2021 Category: Consumer Health News Source Type: news

Ichnos Sciences Appoints Michael D. Price As CFO
NEW YORK, March 2, 2021 -- (Healthcare Sales & Marketing Network) -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today named Michael D. Price as Chief Financial Office... Biopharmaceuticals, Oncology, Personnel Ichnos Sciences, BEAT platform (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 2, 2021 Category: Pharmaceuticals Source Type: news

UCLA forms research collaboration with Yuyu Pharma to advance MS treatment
Through a new collaboration with a South Korean pharmaceutical company, UCLA scientists will participate in the process to develop a new drug to treat multiple sclerosis.UCLA and Yuyu Pharma will evaluate the efficacy and safety of drugs that have the potential to treat the debilitating disease.The collaboration was facilitated by theUCLA Technology Development Group, which manages UCLA ’s intellectual property and spearheads partnerships with private industry to commercialize UCLA research.“We are excited that Yuyu Pharma chose UCLA as its first academic institution partner in the U.S.,” said Amir Naiber...
Source: UCLA Newsroom: Health Sciences - March 1, 2021 Category: Universities & Medical Training Source Type: news

Is Dermatographia an Autoimmune Disease?
Title: Is Dermatographia an Autoimmune Disease?Category: Diseases and ConditionsCreated: 2/25/2021 12:00:00 AMLast Editorial Review: 2/25/2021 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - February 25, 2021 Category: Dermatology Source Type: news

Orna Therapeutics Launches with over $100M Raised to Develop a New Class of Fully Engineered Circular RNA Therapies
Synthetic circular RNA (oRNA) combines nature-driven insights with rational design to produce a bold new class of RNA therapeutics Therapeutic potential across a broad range of diseases including cancer, autoimmune, and genetic disorders CAMBRIDGE, M... Biopharmaceuticals, Venture Capital Orna Therapeutics, circular RNA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 24, 2021 Category: Pharmaceuticals Source Type: news

Checkpoint Inhibitor Safety in Preexisting Autoimmune Diseases Checkpoint Inhibitor Safety in Preexisting Autoimmune Diseases
' To our knowledge, this is the first study to bridge this knowledge gap by presenting'real-world'data on the safety and efficacy of ICI on a national scale,'wrote Monique K. van der Kooij, MD.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - February 17, 2021 Category: Rheumatology Tags: Hematology-Oncology News Source Type: news

Covid-19 Vaccines And Autoimmune Disease
What are recommendations for Covid-19 vaccinations in patients with autoimmune diseases like lupus or rheumatoid arthritis? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 17, 2021 Category: Pharmaceuticals Authors: Judy Stone, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Radiological images confirm 'COVID-19 can cause the body to attack itself'
(Northwestern University) Muscle soreness and achy joints are common symptoms among COVID-19 patients. But for some people, symptoms are more severe, long lasting and even bizarre, including rheumatoid arthritis flares, autoimmune myositis or 'COVID toes.' A new Northwestern Medicine study has, for the first time, confirmed and illustrated the causes of these symptoms through radiological imaging. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 17, 2021 Category: Infectious Diseases Source Type: news

Mimicking a chronic immune response changes the brain
(University of Tsukuba) Abnormal production of Inflammatory cytokines by the immune system is responsible for a host of autoimmune disorders. One important cytokine is IL-17A, which is also involved in neurological diseases. Researchers at Tsukuba University in Japan made a mouse model of chronically high IL-17A and to study its effect on the brain. They show that it leads to reduced activity and density of microglia in the brain's hippocampus, but no obvious memory deficits. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 17, 2021 Category: International Medicine & Public Health Source Type: news

ICI Need Not Be Withheld in Those With Autoimmune Disease
TUESDAY, Feb. 16, 2021 -- For patients with advanced melanoma, response to immune checkpoint inhibitors (ICIs) is similar for those with and without preexisting autoimmune disease (AID), according to a study published online Feb. 16 in the Annals of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 16, 2021 Category: Pharmaceuticals Source Type: news

Gene Study Probes Origins of Addison's Disease
TUESDAY, Feb. 16, 2021 -- Gene variants associated with a rare autoimmune disorder called Addison's disease have been pinpointed, according to researchers. " By studying the single largest collection of samples from patients with Addison's disease,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 16, 2021 Category: General Medicine Source Type: news

Covid-19 and Autoimmune Diseases Covid-19 and Autoimmune Diseases
A new review explores the relationship between COVID-19 and autoimmunity and the potential impact of the virus on those with pre-existing autoimmune diseases.Current Opinion in Rheumatology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 15, 2021 Category: Intensive Care Tags: Rheumatology Journal Article Source Type: news

New study identifies the main genetic causes of autoimmune Addison's disease
(The University of Bergen) Scientists from the University of Bergen (Norway) and Karolinska Institutet (Sweden) have discovered the genes involved in autoimmune Addison's disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 12, 2021 Category: International Medicine & Public Health Source Type: news

Safety of Immune Checkpoint Inhibitors in Patients With IBD Safety of Immune Checkpoint Inhibitors in Patients With IBD
Are immune checkpoint inhibitors safe to use in patients with pre-existing autoimmune diseases?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

What is a Lipschultz Ulcer?
Discussion Acute genital ulcers (AGU) are much less common in sexually-naive women than sexually experienced or active women. The differential diagnosis of AGU is large. For sexually active women Herpes simplex virus is the most common cause. Sexually transmitted infections are also included in this differential. In addition to the pain, AGUs can cause distress for the patient and family as possible sexual abuse must be considered. The differential diagnosis of AGU in non-sexually active women includes: Aphthosis Lipschutz ulcer Idiopathic Autoimmune or inflammatory diseases Behcet disease Bullous pemphigoid Inflammato...
Source: PediatricEducation.org - February 8, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors
BEDMINSTER, N.J., Feb. 5, 2021 -- (Healthcare Sales & Marketing Network) -- Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced the... Biopharmaceuticals, Oncology, Personnel Jubilant Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2021 Category: Pharmaceuticals Source Type: news

Alessio Cortellini's immuno-oncology research earns him Young Investigator Award
(AlphaMed Press) Alessio Cortellini, MD, was awarded The Oncologist's 3rd Annual Young Investigator Award for his research on evaluating the risk of immunotherapy treatment to patients with pre?existing autoimmune disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 4, 2021 Category: International Medicine & Public Health Source Type: news

When hyperactive proteins trigger illnesses
(Technical University of Munich (TUM)) Autoimmune diseases, in which the body's own immune system attacks healthy tissue, can be life-threatening and can impact all organs. A research team at the Technical University of Munich (TUM) has now found a possible cause for these self-destructive immune system attacks: a hyperactive RANK protein on the surface of B cells. The research opens the door to new therapeutic possibilities. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2021 Category: Cancer & Oncology Source Type: news

Toward safer steroids: Scientists devise method for improving safety of drug used to treat COVID-19, autoimmune disorders and more
(Scripps Research Institute) Scripps Research scientists bring together multiple technologies to engineer potentially safer glucocorticoids, drugs used to treat COVID-19 and other conditions. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 2, 2021 Category: Infectious Diseases Source Type: news

A disease-associated mutation that weakens ZAP70 autoinhibition enhances responses to weak and self-ligands
The cytoplasmic kinase ZAP70 is critical for T cell antigen receptor (TCR) signaling. The R360P mutation in ZAP70 is responsible for an early-onset familial autoimmune syndrome. The structural location and biochemical signaling effects of the R360P mutation are consistent with weakening of the autoinhibitory conformation of ZAP70. Mice with a ZAP70 R360P mutation and polyclonal TCR repertoires exhibited relatively normal T cell development but showed evidence of increased signaling. In addition, the R360P mutation resulted in enhanced follicular helper T cell expansion after LCMV infection. To eliminate the possibility of ...
Source: Signal Transduction Knowledge Environment - February 2, 2021 Category: Science Authors: Shen, L., Matloubian, M., Kadlecek, T. A., Weiss, A. Tags: STKE Research Articles Source Type: news

How the Coronavirus Turns the Body Against Itself
Some patients struggling with Covid-19 develop antibodies against their own tissues, scientists have found. (Source: NYT Health)
Source: NYT Health - January 28, 2021 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Coronavirus (2019-nCoV) Antibodies medRxiv Nature Immunology (Journal) Science Translational Medicine (Journal) Immune System Autoimmune Diseases Tissue (Human) Source Type: news

Scientists find key function of molecule in cells crucial for regulating immunity
(University of North Carolina Health Care) UNC School of Medicine scientists led by Jenny Ting, PhD, the William Kenan Distinguished Professor of Genetics, and Yisong Wan, PhD, professor of microbiology and immunology, discovered that AIM2 is important for the proper function of regulatory T cells, or Treg cells, and plays a key role in mitigating autoimmune disease. Treg cells are a seminal population of adaptive immune cells that prevents an overzealous immune response, such as those that occurs in autoimmune diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 28, 2021 Category: International Medicine & Public Health Source Type: news